CoChat
Sign Up
Cited by 119Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., Zanchetta, J. R.·2018·Osteoporosis International
DOI 10.1007/s00198-017-4242-6
Open this paper in CoChat — free account

Abstract

We evaluate 38 elderly women who had received long-term denosumab treatment after stopping the drug. Taking into account the gain during treatment and the loss after stopping treatment, they lost 35.5% of the total gain in the spine, 44.6% of the total gain in the femoral neck, and 103.3% in the total hip.Introduction Denosumab (DMAb) is a soluble inhibitor of the receptor activator of nuclear factor-kappaB ligand (RANKL) and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with reversal of the effects attained with treatment.Purpose The aim of this study is to assess changes in BMD after a year of discontinuation of DMAb in a group of postmenopausal women treated with DMAb for 7 or 10 years. Secondly, is to evaluate the occurrence of fragility fractures.Methods Women who had participated in the FREEDOM study and its extension were invited to participate in this follow-up study. BMD at LS and hip and spine X-rays were obtained. Results were compared to the last value obtained while in treatment to assess changes after discontinuation.Results Thirty-eight women, mean age: 81 ± 3.4 years completed study procedures; none had received bisphosphonates after stopping DMAb. Mean gap time between DMAb last dose and the follow-up visit was 17 months (range 16-20 months). Bone mineral density (BMD) decreased significantly in all regions: - 8.1% in LS, - 6% in FN, and - 8.4% in TH. Five (5/38, 13.15%) patients had a fragility fracture, one suffered a wrist fracture, and four experienced vertebral fractures. Three patients suffered one vertebral fracture and one of them had two vertebral fractures. Laboratory results showed the following mean values: CTX = 996 ± 307 pg/ml (normal values 550 ± 226 pg/ml); osteocalcin = 55.2 ± 18.6 ng/ml (normal value 42 ng/ml); and 25 OH vitamin D = 23.7 ± 6.9 ng/ml.Conclusion Our results describe the rapid bone loss occurring after cessation of denosumab treatment. Further studies are needed to assess if patients have a higher risk of fracture after stopping DMAb and if so, which patients have the highest risk, and assess the role of transitioning to bisphosphonates in the long term.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00198-017-4242-6

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 20 references

Cited by

Sorted by citations

Items 101–118 of 118

Related

See all

Metadata

Authors
Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., & Zanchetta, J. R.
Affiliations
  • Universidad del Salvador (AR)
  • Instituto de Diagnóstico e Investigaciones Metabólicas (AR)
Corresponding author
Zanchetta, M. B.
ORCID
Venue
Osteoporosis International
Publisher
Springer Science and Business Media LLC
Published
2017-10-03
Volume
29
Issue
1
Pages
41-47
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
DOI
10.1007/s00198-017-4242-6
OpenAlex
W2764233026
Cited by
119
References
20
Citations by year
2026: 9 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 10 · 2021: 19 · 2020: 11 · 2019: 19 · 2018: 9
FWCI
11.78
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (unspecified)
Locations
  • Osteoporosis International (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
denosumab, RANKL inhibitor, treatment discontinuation, bone loss, bone mineral density, postmenopausal women, older women, fragility fractures, vertebral fractures, osteocalcin, CTX, 25-hydroxyvitamin D, osteoporosis, bisphosphonates
MeSH terms
Deprescriptions, Denosumab, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Femur Neck, Follow-Up Studies, Hip Joint, Humans, Lumbar Vertebrae, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Withholding Treatment, Bone Density Conservation Agents, Osteoporotic Fractures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review